On 4 March 2020 the Competition and Markets Authority announced its decisions to fine four pharmaceutical companies for breaking competition law. The CMA's investigation into the suppliers of the antidepressant drug nortriptyline has resulted in fines of over £3.4 million, as well as a payment of £1 million to the NHS and the disqualification of a director. These decisions are part of the CMA's ongoing crackdown on illegal cartels and follow the launch of its 'Cheating or Competing?' campaign.
Also in this newsletter
- Speech by CMA's Andrea Coscelli on CMA interventionism in merger control
- China's SAMR conditionally approves Danaher's proposed acquisition of General Electric's biopharma business
- European Commission fines Hotel Group Meliá for restrictive clauses in contracts with tour operators